{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:02:16Z","timestamp":1787900536945,"version":"build-2784847793"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,2,20]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long-term efficacy and safety of oral saffron, a natural antioxidant, in treating mild\/moderate age-related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Open-label, extension trial of 93 adults (&gt;50 years) with mild\/moderate AMD and vision &gt;20\/70 Snellen equivalent in at least 1 eye. Exclusion criteria included confounding visual lesions or significant gastrointestinal disease impairing absorption.<\/jats:p>\n                    <jats:p>Participants were given oral saffron supplementation (20\u2009mg\/day) for 12 months. Those already consuming Age-Related Eye Diseases Study (AREDS) supplements or equivalent maintained these.<\/jats:p>\n                    <jats:p>Primary outcomes included changes in multifocal electroretinogram (mfERG) response density and latency, and changes in best-corrected visual acuity (BCVA). Secondary outcomes included safety outcomes, changes in mfERG and BCVA among participants on AREDS supplements and changes in microperimetry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12 months, mean mfERG response density was significantly higher in rings 1, 2 and overall (p&lt;0.001 for all) but not in rings 3\u20136, and there was no difference in response between those taking AREDS supplements and those not (p&gt;0.05). Mean mfERG latency was not significantly different in any of rings 1\u20136 or overall (p&gt;0.05 for all), again with no difference between those taking AREDS supplements or not (p&gt;0.05). Mean BCVA was 1.6 letters worse (p&lt;0.05) with no difference between those on AREDS supplements or not, and this may have been related to cataract progression. No saffron-related serious adverse events were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Saffron supplementation modestly improved mfERG responses in participants with AMD, including those using AREDS supplements. Given the chronic nature of AMD, longer-term supplementation may produce greater benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001399","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:05:16Z","timestamp":1710374716000},"page":"e001399","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Saffron therapy for the ongoing treatment of age-related macular degeneration"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-4513","authenticated-orcid":false,"given":"Geoffrey K","family":"Broadhead","sequence":"first","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia"},{"name":"Sydney Retina Clinic, Sydney, New South Wales, Australia"},{"name":"Cureos, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-8119","authenticated-orcid":false,"given":"John","family":"Grigg","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"McCluskey","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hong","sequence":"additional","affiliation":[{"name":"Sydney Retina Clinic, Sydney, New South Wales, Australia"},{"name":"Cureos, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E","family":"Schlub","sequence":"additional","affiliation":[{"name":"The University of Sydney School of Public Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Chu","sequence":"additional","affiliation":[{"name":"Sydney Retina Clinic, Sydney, New South Wales, Australia"},{"name":"Cureos, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1585","authenticated-orcid":false,"given":"Andrew A","family":"Chang","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia"},{"name":"Sydney Retina Clinic, Sydney, New South Wales, Australia"},{"name":"Cureos, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2025090109314357000_9.1.e001399.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.11.041"},{"key":"2025090109314357000_9.1.e001399.2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.oret.2019.07.015","article-title":"Developing therapies for age-related macular degeneration: the art and science of problem-solving: the 2018 Charles L","volume":"3","author":"Miller","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"2025090109314357000_9.1.e001399.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.02.030"},{"key":"2025090109314357000_9.1.e001399.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.4997"},{"key":"2025090109314357000_9.1.e001399.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025090109314357000_9.1.e001399.6","unstructured":"Heir JS , Lad EM , et al . n.d. Pegcetoacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two Multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet;2023:1434\u201348."},{"key":"2025090109314357000_9.1.e001399.7","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/OPTH.S409103","article-title":"Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway","volume":"17","author":"Reitan","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"2025090109314357000_9.1.e001399.8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-018-4163-x","article-title":"Saffron therapy for the treatment of mild\/moderate age-related macular degeneration: a randomised clinical trial","volume":"257","author":"Broadhead","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025090109314357000_9.1.e001399.9","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4995"},{"key":"2025090109314357000_9.1.e001399.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052592","article-title":"Exudative versus Nonexudative age-related macular degeneration: pathophysiology and treatment options","volume":"23","author":"Fernandes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025090109314357000_9.1.e001399.11","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1080\/10408398.2013.879467","article-title":"Efficacy and safety of Saffron supplementation: Current clinical findings","volume":"56","author":"Broadhead","year":"2016","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2025090109314357000_9.1.e001399.12","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8214821","article-title":"The pharmacological activities of Crocus sativus L.:A review on the mechanisms and therapeutic Opportunties of its Phytoconstituents","volume":"2022","author":"Butnariu","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"2025090109314357000_9.1.e001399.13","first-page":"570","article-title":"A simplified severity scale for age-related macular degeneration: AREDS report number 18","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"2025090109314357000_9.1.e001399.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-014-9473-7"},{"key":"2025090109314357000_9.1.e001399.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00732-7"},{"key":"2025090109314357000_9.1.e001399.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-011-9296-8"},{"key":"2025090109314357000_9.1.e001399.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-016-9545-y"},{"key":"2025090109314357000_9.1.e001399.18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10633-015-9507-9","article-title":"The value of multifocal electroretinography to predict progressive visual loss in early AMD","volume":"131","author":"Ambrosio","year":"2015","journal-title":"Doc Ophthalmol"},{"key":"2025090109314357000_9.1.e001399.19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025090109314357000_9.1.e001399.20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14407"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:31:49Z","timestamp":1756744309000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bmjophth-2023-001399"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001399","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}